The Dasatinib caproKit represents an ideal profiling system to investigate tyrosine kinases
Tyrosine kinases are a subclass of protein kinases which are key players in signal transduction in cellular systems. Tyrosine kinases play pivotal roles in diverse cellular activities including growth, differntiation, metabolism, adhesion, motility, and death (1).
From the approximately 90 tyrosine kinases encoded in the human genome 58 are expressed as receptors on the cell surface (2).
Many tyrosine kinases are involved in oncogenesis, either by gene mutation, or chromosome translocation (3), or simply by over-expression. In every case, the result is an over-active kinase that confers an aberrant, ligand-independent and non-regulated growth stimulus to the cancer cells.
Dasatinib is an ATP-competitive and multi-targeted small molecule inhibitor of BCR-ABL and Src with potency in the low nanomolar range (4). The compound has recently been approved for use in Ph+ (Philadelphia+) leukemias (5).
With its broader range of activity against BCR-ABL forms (6) dasatinib is an ideal selectivity function for tyrosine kinase-specific Capture Compound™ which allows an improved experimental access to this important subgroup of kinases.
The Dasatinib caproKit™ includes the Dasatinib Capture Compound, Dasatinib competitor, all buffers, positive control protein, and streptavidin magnetic beads.
Please note, that CCMS reagents (caproKits™) will perform best when used with the optimized equipment (caproBox™ and caproMag™).
For the most reproducible results it is recommended to standardize parameters such as UV wavelength, distance between sample and light source, temperature and incubation time. This can best be accomplished using a caproBox™ for cross-linking.
If you are using the proprietary CCMS technology for the first time, caprotec offers a convenient CCMS Starter Kit including a free choice of 3 independent caproKits™, Biotin Capping Kit, caproBox™, and caproMag™. Please feel free to contact us for any additional questions related to using caprotec products!
References:
1) S.B. Bhise, A.D. Nalawade, H. Wadhawa (2004) Role of protein tyrosine kinase inhibitors in cancer therapeutics; Indian J. Biochem. Biophys. (41); 273-280; ISSN 0301-1208.
